Blueprint Medicines
BPMC
108,90 €
Share price
0.05%
Change (1 day)
7.08%
Change (1 year)
Categories
Blueprint Medicines (BPMC) - Total debt
Total debt on the balance sheet as of March 2025 : €0.39 Billion
According to Blueprint Medicines 's latest financial reports the company's total debt is €0.39 Billion. A company’s total debt is the sum of all current and non-current debts.
Blueprint Medicines - Total debt on balance sheet (from 2014 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | €0.45 B | 49.88% |
| 2023-12-31 | €0.30 B | 33.07% |
| 2022-12-31 | €0.22 B | 129.76% |
| 2021-12-31 | €98.37 M | 35.04% |
| 2020-12-31 | €72.84 M | -14.95% |
| 2019-12-31 | €85.65 M | 570.35% |
| 2018-12-31 | €12.77 M | -14.11% |
| 2017-12-31 | €14.87 M | 110.34% |
| 2016-12-31 | €7.07 M | -31.48% |
| 2015-12-31 | €10.32 M | 38.84% |
| 2014-12-31 | €7.43 M | 258.62% |
| 2013-12-31 | €2.07 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Isoray
ISR | €0.33 M | -99.92% | 🇺🇸 USA |
 OPKO Health
OPK | €0.41 B | 5.61% | 🇺🇸 USA |
 Pacific Biosciences
PACB | €0.59 B | 49.80% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |